Vikas Pandey

Vikas Pandey

Auto-generated profile, based on publicly available information

Vikas Pandey

Rensselaer Polytechnic Institute (United States)

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2024 in Optics Letters
Verified
Journal Article
Closed access
PDF file
VPVikas Pandey
Vikas Pandey
IEIsmail Erbas
Ismail Erbas
XMXavier Michalet
Xavier Michalet
AUArin Ulku
Arin Ulku
CBClaudio Bruschini
Claudio Bruschini
XIXavier Intes
Xavier Intes
The acquisition of the time of flight (ToF) of photons has found numerous applications in the biomedical field. Over the last decades, a few strategies have been proposed to deconvolve the temporal instrument response function (IRF) that distorts the experimental time-resolved data. However, these methods require burdensome computational strategies and regularization terms to mitigate noise contributions. Herein, we propose a deep learning model specifically to perform the deconvolution task in fluorescence lifetime imaging (FLI). The model is trained and validated with representative simulated FLI data with the goal of retrieving the true photon ToF distribution. Its performance and robustness are validated with well-controlled in vitro experiments using three time-resolved imaging modalities with markedly different temporal IRFs. The model aptitude is further established with in vivo preclinical investigation. Overall, these in vitro and in vivo validations demonstrate the flexibility and accuracy of deep learning model-based deconvolution in time-resolved FLI and diffuse optical imaging.

9 December 2025 in Optics Letters
Verified
Journal Article
Closed access
NYNanxue Yuan
Nanxue Yuan
SRSaif Ragab
Saif Ragab
LCLuis Chavez
Luis Chavez
VPVikas Pandey
Vikas Pandey
XIXavier Intes
Xavier Intes
Fluorescence lifetime imaging (FLI) offers valuable insights into the molecular and functional properties of biological tissues. However, in deeper tissues, optical properties (scattering and absorption) diminish fluorescence signal significantly and complicate data interpretation. This study explores the potential of tartrazine (FD&C Yellow 5), a biocompatible and FDA-approved food dye, as an optical clearing agent for deep tissue imaging. Despite its own near-infrared (NIR) fluorescence, tartrazine’s ultrashort intrinsic lifetime (∼0.10 ns) allows for effective separation from the longer lifetimes of conventional NIR probes (>0.50 ns) using lifetime-based unmixing. We found that at an optimal concentration (≤ 0.6 M), tartrazine brings down the reduced scattering coefficient ( μ s ′ ) by more than 90%, significantly improving fluorescence signal recovery from deeper tissue regions. Our validation with multi-depth tissue phantoms showed that this method can accurately recover fluorescence signals and lifetimes from targets located more than 1 cm deep, achieving results comparable to low-scattering controls. These findings show that tartrazine is a practical and effective optical clearing agent that can enhance the depth, resolution, and quantitative accuracy of FLI in highly scattering media, such as those used in preclinical imaging studies.

19 December 2025 in PhotoniX
Verified
Journal Article
Open access
PDF file
VPVikas Pandey
Vikas Pandey
EMEuan Millar
Euan Millar
IEIsmail Erbas
Ismail Erbas
LCLuis Chavez
Luis Chavez
JRJack Radford
Jack Radford
XIXavier Intes
Xavier Intes
Fluorescence lifetime imaging (FLI) is a powerful tool for investigating molecular processes, microenvironmental parameters, and molecular interactions across tissue to (sub-)cellular levels. Despite its established value in biomedical applications, conventional FLI techniques suffer from long acquisition times, limiting their utility in real-time scenarios like fast biological processes and rapid clinical image-guided interventions. Here, we introduce a novel FLI approach that achieves real-time capability through single-snapshot acquisitions by combining a large-format time-gated SPAD array with dual-gate acquisition capability and a rapid lifetime determination algorithm, thus eliminating time-consuming temporal data collection. We demonstrate this method’s scalability and versatility across challenging biomedical applications, such as fast neural dynamics (microscale), multimodal 3D volumetric FLI of tumor organoids (mesoscale), and FLI-guided surgical procedures using tissue-mimicking phantoms (macroscale). Overall, this new methodology significantly enhances FLI’s temporal and spatial capabilities, enabling rapid dynamic biomedical signal acquisition and seamless integration into clinical workflows, particularly fluorescence-guided surgery.

27 December 2022 in Sustainable Energy Technologies and Assessments
Verified
Journal Article
Closed access
KKKashish Kumar
Kashish Kumar
ASAlok Singh
Alok Singh
PCPREM KUMAR CHAURASIYA
PREM KUMAR CHAURASIYA
KPKamal Kishore Pathak
Kamal Kishore Pathak
VPVikas Pandey
Vikas Pandey

6 October 2025 in Journal of Physics: Photonics
Verified
Journal Article
Open access
PDF file
NYNanxue Yuan
Nanxue Yuan
SRSaif Ragab
Saif Ragab
NNNavid Ibtehaj Nizam
Navid Ibtehaj Nizam
VPVikas Pandey
Vikas Pandey
AVAmit Verma
Amit Verma
XIXavier Intes
Xavier Intes
Macroscopic fluorescence lifetime imaging (MFLI) has emerged as a robust, non-invasive imaging technique offering quantitative insights into physiological and molecular processes within live tissues, independent of fluorophore concentration, excitation intensity, or signal attenuation. However, a key limitation is the inability to accurately determine the depth at which fluorescence signals originate, potentially compromising biological interpretation due to ambiguous localization. In this study, we introduce high spatial frequency-fluorescence lifetime imaging (HSF-FLI), an innovative optical correction methodology designed to effectively eliminate surface signal bias, such as those arising from skin in preclinical imaging, without requiring chemical clearing agents. We develop a modulation transfer function linking spatial frequency with signal penetration depth through comprehensive Monte Carlo eXtreme simulations. Utilizing structured, three-phase sinusoidal illumination, fluorescence signals were accurately decomposed into distinct surface and subsurface components. Experimental validation was performed using agar-based capillary phantoms and a time-gated intensified charged coupled device coupled with a digital micromirror device imaging system. Further demonstrating its practical utility, we successfully applied HSF-FLI to preclinical drug delivery assessments employing Förster resonance energy transfer MFLI. The method was rigorously validated in vivo using mouse tumor xenograft models and cross-validated through ex vivo analyses. Overall, by integrating structure illumination techniques with physics-based depth modeling, HSF-FLI achieves precise depth-selective FLI. This advancement significantly enhances the accuracy, biological interpretation, and applicability of FLI, positioning HSF-FLI as a valuable tool for translational research.

13 March 2024
Verified
Conference Paper
Closed access
PDF file
NYNanxue Yuan
Nanxue Yuan
VPVikas Pandey
Vikas Pandey
AVAmit Verma
Amit Verma
JWJohn C. Williams
John C. Williams
XIXavier Intes
Xavier Intes
MBMargarida M. Barroso
Margarida M. Barroso
Emergent breast tumor resistance and tumor microenvironment (TME) heterogeneity can lead to decreased drug delivery efficacy, resulting in therapeutic failure. Preclinical molecular imaging is a crucial tool in the advancement of targeted therapeutics for supporting the development of new drugs but also to elucidate factors hampering optimal drug delivery. However, noninvasive tumor imaging modalities that can quantify drug-target engagement, which is critical for therapeutic actuation, are still lacking. We have demonstrated the utility of macroscopic fluorescence lifetime Forster’s Resonance Energy Transfer (MFLI FRET)-based optical imaging to measure labeled trastuzumab (TZM)-human epidermal growth factor receptor (HER2) binding in human HER2+ cell lines and breast tumor xenograft mice models. We have established a clinically relevant TZM antibody drug containing the Meditope (MDT) peptide conjugated to near-infrared (NIR) dyelabeled FRET pairs, that retain full HER2 binding capability. Herein, we demonstrate FRET measurements using MFLI in vivo imaging platform to measure the ability of MDT-TZM to bind HER2 in living breast tumor xenografts. HER2+ AU565 breast tumor xenografts bearing nude mice were injected retro-orbitally with TZM (NHS-conjugated) or MDTTZM labeled with AlexaFluor700 (donor) and AlexaFluor750 (acceptor) and MFLIFRET imaging was performed 24 h and 48 h post-injection. Preliminary data suggest that MDT-TZM shows higher uniform and consistent FRET signal compared to TZM, suggesting increased efficacy of TZM-MDT-HER2 binding. Also staggered injections of donor and acceptor MDT-TZM may be optimal for quantifying MDT-TZM using MFLIFRET compared to single injections.